Table 8 Complete abstinence from week 2 at each visit
Time since treatment started | 6 weeks | 12 weeks | 26 weeks | ||||
|---|---|---|---|---|---|---|---|
French study (FTDN 4 to7) | Placebo n = 222, Nicotinell Lozenge 1 mg n = 211 | ||||||
Completely abstinent | active | 48 | 22.7% | 28 | 13.3% | 25 | 11.8% |
N (%) | placebo | 32 | 14.4% | 20 | 9.0% | 18 | 8.1% |
OR [95% CI] | 1.72 [1.05–2.80] | 1.47 [0.82–2.65] | 1.48 [0.78–2.79] | ||||
Statistical significance | p = 0.03 | p = 0.199 | p = 0.227 | ||||
USA study (FTND ≥ 6) | Placebo n = 230, Nicotinell Lozenge 1 mg n = 230 | ||||||
Completely abstinent | active | 19 | 8.3% | 11 | 4.8% | 8 | 3.5% |
N (%) | placebo | 7 | 3.0% | 3 | 1.3% | 2 | 0.9% |
OR [95% CI] | 2.87 [1.18–6.97] | 3.80 [1.05–13.80] | 4.11 [0.83–19.55] | ||||
Statistical significance | p = 0.02 | p = 0.03 | p = 0.06 | ||||